← Leaderboards
Thomas F Gajewski
University Of Chicago
$23,743,716
Attributed
$23,743,716
Total exposure
20
Grants
16
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.9M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$23,743,716 · 20
By mechanism
R35$9,380,355 · 1
R01$9,042,268 · 8
P30$2,788,480 · 6
P01$1,366,773 · 1
R21$1,165,840 · 3
M01$0 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Chicago
Same institution · by research overlap
- Michelle M Le Beau$39,023,275
- Yimin Zou$16,553,198
- Kunle O Odunsi$16,178,755
- Barbara Lynn Golden$1,762,354
- Brian Baker$13,388
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorT-LymphocyteCellsImmune ResponseImmuneTumor ImmunityImmunotherapyIn VivoMalignant NeoplasmsFundingMelanomaResponseTumor AntigensTumor MicroenvironmentCancer ImmunotherapyBaseResearch PersonnelLaboratoriesImmunologicsImmunotherapeutic AgentT Cell ResponseGene Expression ProfilingClinical ApplicationInvestigation
Grant awards (87)
Overcoming resistance to anti-PD1 immunotherapy$970,173
R35 · FY2025 · CA · contact PI
Immunology and Cancer$213,099
P30 · FY2025 · CA · contact PI
Human Immunologic Monitoring Facility$213,098
P30 · FY2025 · CA · contact PI
Overcoming resistance to anti-PD1 immunotherapy$893,950
R35 · FY2024 · CA · contact PI
Human Immunologic Monitoring Facility$97,818
P30 · FY2024 · CA · contact PI
Immunology and Cancer$46,927
P30 · FY2024 · CA · contact PI
Overcoming resistance to anti-PD1 immunotherapy$970,168
R35 · FY2023 · CA · contact PI
Overcoming resistance to anti-PD1 immunotherapy$927,149
R35 · FY2023 · CA · contact PI
Overcoming resistance to anti-PD1 immunotherapy$924,579
R35 · FY2022 · CA · contact PI
Human Immunologic Monitoring and cGMP$220,445
P30 · FY2022 · CA · contact PI
Immunology and Cancer$46,088
P30 · FY2022 · CA · contact PI
Overcoming resistance to anti-PD1 immunotherapy$943,344
R35 · FY2021 · CA · contact PI
Human Immunologic Monitoring and cGMP$221,729
P30 · FY2021 · CA · contact PI
Immunology and Cancer$46,358
P30 · FY2021 · CA · contact PI
Overcoming resistance to anti-PD1 immunotherapy$946,072
R35 · FY2020 · CA · contact PI
Human Immunologic Monitoring and cGMP$221,729
P30 · FY2020 · CA · contact PI
Immunology and Cancer$46,358
P30 · FY2020 · CA · contact PI
Immunology and Cancer$4,735
P30 · FY2020 · CA · contact PI
Human Immunologic Monitoring and cGMP$4,735
P30 · FY2020 · CA · contact PI
Overcoming resistance to anti-PD1 immunotherapy$917,690
R35 · FY2019 · CA · contact PI
Human Immunologic Monitoring and cGMP$221,729
P30 · FY2019 · CA · contact PI
Immunology and Cancer$46,358
P30 · FY2019 · CA · contact PI
Overcoming resistance to anti-PD1 immunotherapy$946,072
R35 · FY2018 · CA · contact PI
Human Immunologic Monitoring and cGMP$228,316
P30 · FY2018 · CA · contact PI
Immunology and Cancer$44,431
P30 · FY2018 · CA · contact PI
Human Immunologic Monitoring and cGMP$2,728
P30 · FY2018 · CA · contact PI
Immunology and Cancer$2,727
P30 · FY2018 · CA · contact PI
Immunology and Cancer$2,621
P30 · FY2018 · CA · contact PI
Human Immunologic Monitoring and cGMP$2,620
P30 · FY2018 · CA · contact PI
Overcoming resistance to anti-PD1 immunotherapy$941,158
R35 · FY2017 · CA · contact PI
Germline and somatic variants associated with melanoma immunophenotype$432,530
R01 · FY2016 · CA · contact PI
Host STING pathway in anti-tumor immunity$327,850
R01 · FY2016 · CA · contact PI
EGR2 in T cell tolerance$327,850
R01 · FY2016 · CA · contact PI
EGR2 in T cell tolerance$327,850
R01 · FY2015 · CA · contact PI
Host STING pathway in anti-tumor immunity$327,850
R01 · FY2015 · CA · contact PI
Host STING pathway in anti-tumor immunity$327,850
R01 · FY2014 · CA · contact PI
EGR2 in T cell tolerance$318,015
R01 · FY2014 · CA · contact PI
EGR2 in T cell tolerance$308,179
R01 · FY2013 · CA · contact PI
EGR2 in T cell tolerance$327,850
R01 · FY2012 · CA · contact PI
Innate Factors in Tumor Antigen Cross-Presentation$269,433
P01 · FY2012 · CA · contact PI
PROGRAM 3 (IMMUNOLOGY AND CANCER)$139,999
P30 · FY2012 · CA · contact PI
HUMAN IMMUNOLOGIC MONITORING$122,269
P30 · FY2012 · CA · contact PI
PROGRAM 3 (IMMUNOLOGY AND CANCER)$23,633
P30 · FY2012 · CA · contact PI
Countering immune resistance in the melanoma tumor microenvironment$274,661
R01 · FY2011 · CA · contact PI
Innate Factors in Tumor Antigen Cross-Presentation$267,400
P01 · FY2011 · CA · contact PI
HUMAN IMMUNOLOGIC MONITORING$128,217
P30 · FY2011 · CA · contact PI
PROGRAM 3 (IMMUNOLOGY AND CANCER)$24,777
P30 · FY2011 · CA · contact PI
DGK in T Cell Regulation and Tolerance$390,000
R01 · FY2010 · AI · contact PI
Countering immune resistance in the melanoma tumor microenvironment$291,650
R01 · FY2010 · CA · contact PI
Innate Factors in Tumor Antigen Cross-Presentation$276,224
P01 · FY2010 · CA · contact PI
T Cell Responsiveness and Homeostasis in Anti-Tumor$261,011
R01 · FY2010 · CA · contact PI
HUMAN IMMUNOLOGIC MONITORING$139,619
P30 · FY2010 · CA · contact PI
PROGRAM 3 (IMMUNOLOGY AND CANCER)$26,979
P30 · FY2010 · CA · contact PI
DGK in T Cell Regulation and Tolerance$390,000
R01 · FY2009 · AI · contact PI
Countering immune resistance in the melanoma tumor microenvironment$291,650
R01 · FY2009 · CA · contact PI
Innate Factors in Tumor Antigen Cross-Presentation$272,268
P01 · FY2009 · CA · contact PI
T Cell Responsiveness and Homeostasis in Anti-Tumor$261,011
R01 · FY2009 · CA · contact PI
Deletion of inhibitory genes in post-thymic T cells to study immune tolerance$192,500
R21 · FY2009 · AI · contact PI
HUMAN IMMUNOLOGIC MONITORING$127,583
P30 · FY2009 · CA · contact PI
PROGRAM 3 (IMMUNOLOGY AND CANCER)$24,656
P30 · FY2009 · CA · contact PI
Countering immune resistance in the melanoma tumor microenvironment$291,650
R01 · FY2008 · CA · contact PI
Innate Factors in Tumor Antigen Cross-Presentation$281,448
P01 · FY2008 · CA · contact PI
T Cell Responsiveness and Homeostasis in Anti-Tumor$261,011
R01 · FY2008 · CA · contact PI
Deletion of inhibitory genes in post-thymic T cells to study immune tolerance$231,000
R21 · FY2008 · AI · contact PI
HUMAN IMMUNOLOGIC MONITORING$80,536
P30 · FY2008 · CA · contact PI
PROGRAM 3 (IMMUNOLOGY AND CANCER)$15,563
P30 · FY2008 · CA · contact PI
Countering immune resistance in the melanoma tumor microenvironment$291,650
R01 · FY2007 · CA · contact PI
T Cell Responsiveness and Homeostasis in Anti-Tumor$261,011
R01 · FY2007 · CA · contact PI
T Cell Responsiveness and Homeostasis in Anti-Tumor$268,816
R01 · FY2006 · CA · contact PI
Multi-Peptide/IL 12 Melanoma Vaccine$265,071
R01 · FY2006 · CA · contact PI
Biochemical/Molecular Changes Upon Naive T Cell Priming$282,549
R01 · FY2005 · AI
Multi-Peptide/IL 12 Melanoma Vaccine$271,450
R01 · FY2005 · CA
Molecular Dissection of T Cell Anergy$223,710
R21 · FY2005 · AI
Biochemical/Molecular Changes Upon Naive T Cell Priming$282,732
R01 · FY2004 · AI
Multi-Peptide/IL 12 Melanoma Vaccine$271,450
R01 · FY2004 · CA
Molecular Dissection of T Cell Anergy$223,710
R21 · FY2004 · AI
Biochemical/Molecular Changes Upon Naive T Cell Priming$278,887
R01 · FY2003 · AI
Multi-Peptide/IL 12 Melanoma Vaccine$271,450
R01 · FY2003 · CA
Technologies To Block Gene Expression in Normal T Cells$147,460
R21 · FY2003 · AI
Biochemical/Molecular Changes Upon Naive T Cell Priming$279,211
R01 · FY2002 · AI
Technologies To Block Gene Expression in Normal T Cells$147,460
R21 · FY2002 · AI
Core--Human immunologic monitoring$0
P30 · FY2002 · CA
Core--Human immunologic monitoring$0
P30 · FY2002 · CA
MAGE-3 PLUS IL-12 IMMUNIZATION IN METASTATIC MELANOMA$0
M01 · FY2002 · RR
Biochemical/Molecular Changes Upon Naive T Cell Priming$279,523
R01 · FY2001 · AI
MAGE-3 PLUS IL-12 IMMUNIZATION IN METASTATIC MELANOMA$0
M01 · FY2000 · RR
MAGE-3 PLUS IL-12 IMMUNIZATION IN METASTATIC MELANOMA$0
M01 · FY2000 · RR